Download presentation
Presentation is loading. Please wait.
Published byJuniper Hodges Modified over 6 years ago
1
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly van der Hoek, MSc, Barbara Melosky, MD, Stuart Peacock, MSc Journal of Thoracic Oncology Volume 6, Issue 12, Pages (December 2011) DOI: /JTO.0b013e31822f657a Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
2
FIGURE 1. Kaplan-Meier estimates of overall survival of erlotinib and comparative groups. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822f657a) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
3
FIGURE 2. Kaplan-Meier estimates of progression-free survival in erlotinib and comparative groups. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822f657a) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
4
FIGURE 3. Proportional costs in erlotinib and comparative groups.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822f657a) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
5
FIGURE 4. 1000 Monte-Carlo sampled incremental cost-effectiveness ratios of erlotinib versus comparative group. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822f657a) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
6
FIGURE 5. Percentage of incremental cost-effectiveness ratios falling below cost-effectiveness thresholds. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822f657a) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.